home / press / releases

Menu
  • Search all tables

releases: https://www.mccormick.senate.gov/news/press-releases/senator-mccormick-celebrates-eli-lillys-3-5-billion-investment-in-the-lehigh-valley/

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://www.mccormick.senate.gov/news/press-releases/senator-mccormick-celebrates-eli-lillys-3-5-billion-investment-in-the-lehigh-valley/ SENATOR MCCORMICK CELEBRATES ELI LILLY’S $3.5 BILLION INVESTMENT IN THE LEHIGH VALLEY 2026-11-12 2026 2026-11 Republican Senate PA David McCormick M001243 www.mccormick.senate.gov davemccormick https://www.mccormick.senate.gov/newsroom/press-releases/ scraper FOGELSVILLE, PA — U.S. Senator Dave McCormick (R-PA) today celebrated Eli Lilly and Company’s announcement of a $3.5 billion pharmaceutical manufacturing facility in Fogelsville, Pennsylvania, in the Lehigh Valley. The investment is expected to create 850 high-paying permanent jobs and approximately 2,000 construction jobs, further strengthening Pennsylvania’s position as a national leader in life sciences, innovation, and advanced manufacturing. “Lilly’s $3.5 billion investment in the Lehigh Valley is another major win for Pennsylvania, bringing 850 high-paying jobs, strengthening American manufacturing, and cementing the Commonwealth’s position as a leader in life sciences,” said Senator McCormick. “When I talk about building a pro-growth environment in Pennsylvania, this is the type of investment I am working to attract.” Senator McCormick is proud to have worked alongside Eli Lilly Chairman and CEO David A. Ricks and the Governor to help bring this significant investment to the Lehigh Valley. The project represents another major step toward expanding Pennsylvania’s economy, attracting private-sector investment, and creating new opportunities for Pennsylvania workers and families. The facility will produce next-generation injectable medicines using advanced technologies, including AI and automation. It is expected to be operational by 2031. As part of the investment, Lilly also plans to provide up to $1 million over five years to the Upper Macungie Township Community Fund to support community programs focused on nutrition, healthy living, access to fresh food, and other health resources. The Lehigh Valley facility is part of Lilly’s broader $50 billion commitment to expanding pharmaceutical manufacturing sites the company has announced since 2020. 1 2026-11-13T12:52:09Z 2026-11-13T12:53:11Z
Powered by Datasette · Queries took 0.814ms · Data license: MIT · Data source: dwillis/congress-press